Literature DB >> 21682978

Xpert MTB/RIF®, a novel automated polymerase chain reaction-based tool for the diagnosis of tuberculosis.

E C Bowles1, B Freyée, J van Ingen, B Mulder, M J Boeree, D van Soolingen.   

Abstract

There is an urgent need for new point of care tests for tuberculosis (TB). Xpert MTB/RIF® is a real-time polymerase chain reaction-based system that detects Mycobacterium tuberculosis DNA and rifampicin (RMP) resistance modulating mutations directly from clinical samples in 2 h. The sensitivity for detecting M. tuberculosis in culture-positive samples was 93.8% (60/64) and exceeded smear microscopy (40/64, 62.5%). The specificity for detecting M. tuberculosis was 92.0% (23/25) and for RMP resistance it was 100% (8/8). The test is simple to conduct and requires basic sputum handling facilities only. These characteristics render it a promising close-to-patient test for TB in various settings.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21682978     DOI: 10.5588/ijtld.10.0574

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  17 in total

Review 1.  Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance.

Authors:  Stephen D Lawn; Mark P Nicol
Journal:  Future Microbiol       Date:  2011-09       Impact factor: 3.165

2.  Comparative Study of GeneXpert with ZN Stain and Culture in Samples of Suspected Pulmonary Tuberculosis.

Authors:  Monika Agrawal; Ashish Bajaj; Vinay Bhatia; Sarjana Dutt
Journal:  J Clin Diagn Res       Date:  2016-05-01

Review 3.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Karen R Steingart; Ian Schiller; David J Horne; Madhukar Pai; Catharina C Boehme; Nandini Dendukuri
Journal:  Cochrane Database Syst Rev       Date:  2014-01-21

4.  Impact of GeneXpert MTB/RIF on patients and tuberculosis programs in a low-burden setting. a hypothetical trial.

Authors:  J Lucian Davis; L Masae Kawamura; Lelia H Chaisson; Jennifer Grinsdale; Jihane Benhammou; Christine Ho; Anna Babst; Houmpheng Banouvong; John Z Metcalfe; Mark Pandori; Philip C Hopewell; Adithya Cattamanchi
Journal:  Am J Respir Crit Care Med       Date:  2014-06-15       Impact factor: 21.405

5.  Performance of the Roche LightCycler real-time PCR assay for diagnosing extrapulmonary tuberculosis.

Authors:  N Gous; L E Scott; E Wong; T Omar; W D F Venter; W Stevens
Journal:  J Clin Microbiol       Date:  2012-04-11       Impact factor: 5.948

6.  Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  David J Horne; Mikashmi Kohli; Jerry S Zifodya; Ian Schiller; Nandini Dendukuri; Deanna Tollefson; Samuel G Schumacher; Eleanor A Ochodo; Madhukar Pai; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2019-06-07

Review 7.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Karen R Steingart; Hojoon Sohn; Ian Schiller; Lorie A Kloda; Catharina C Boehme; Madhukar Pai; Nandini Dendukuri
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

8.  Initial experience with GeneXpert MTB/RIF assay in the Arkansas Tuberculosis Control Program.

Authors:  Naveen Patil; Hamida Saba; Asween Marco; Rohan Samant; Leonard Mukasa
Journal:  Australas Med J       Date:  2014-05-31

9.  Meta-analysis to compare the accuracy of GeneXpert, MODS and the WHO 2007 algorithm for diagnosis of smear-negative pulmonary tuberculosis.

Authors:  Simon Walusimbi; Freddie Bwanga; Ayesha De Costa; Melles Haile; Moses Joloba; Sven Hoffner
Journal:  BMC Infect Dis       Date:  2013-10-30       Impact factor: 3.090

10.  Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous meningitis in a high burden setting: a prospective study.

Authors:  Vinod B Patel; Grant Theron; Laura Lenders; Brian Matinyena; Cathy Connolly; Ravesh Singh; Yacoob Coovadia; Thumbi Ndung'u; Keertan Dheda
Journal:  PLoS Med       Date:  2013-10-22       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.